Trials / Completed
CompletedNCT00452595
Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder
A 12-Month Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Outpatients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the long-term safety of desvenlafaxine sustained release (DVS-233SR) during open-label treatment of outpatients with major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 SR (desvenlafaxine sustained release ) |
Timeline
- Start date
- 2004-01-01
- Completion
- 2005-05-01
- First posted
- 2007-03-27
- Last updated
- 2007-03-27
Source: ClinicalTrials.gov record NCT00452595. Inclusion in this directory is not an endorsement.